Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-3.A1 peptide + CpG 7909 in metastatic melanoma
NCT00145145Phase 2Terminated
- Sponsor
- Ludwig Cancer Research
- Start
- Jan 2005
- Primary completion
- Apr 2005
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of MAGE-3.A1 peptide, agatolimod in melanoma, sponsored by Ludwig Cancer Research. Started Jan 2005; status: terminated.
02
Drugs
MAGE-3.A1 peptideagatolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00145145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145145.